Results 191 to 200 of about 338,947 (383)
Nanozymes emerge as promising therapeutic agents for reactive oxygen species (ROS)‐dependent diseases, offering advantages over traditional biocatalysts through enhanced stability, tunability, and targeting capabilities. This review explores their mechanisms, design strategies, and clinical progress, emphasizing precision medicine potential.
Lihong Zhou+8 more
wiley +1 more source
Suppressor cell function in atopic dermatitis associated with elevated immunoglobulin E
David M. Schuster+3 more
openalex +1 more source
Faecalibacterium Diversity in the Gut Microbiome of Crohn's Disease Patients
ABSTRACT Faecalibacterium has recently garnered attention for its potential health implications. To better understand its role, we developed and assessed real‐time PCR assays for detecting and quantifying various Faecalibacterium species in human stool samples from both healthy individuals and Crohn's disease patients, either in flare or remission. The
Paul Mclellan+16 more
wiley +1 more source
On the significance of the trichophytin reactivity in atopic dermatitis
G Rajka, C. Barlinn
openalex +2 more sources
Loss-of-function variants of the filaggrin gene are associated with atopic eczema and associated phenotypes in Swedish families [PDF]
Bradley, Maria+7 more
core +2 more sources
ABSTRACT Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa characterized by allergen sensitization and the involvement of multiple inflammatory mediators. Currently, the treatment of AR mainly includes symptomatic relief, anti‐inflammatory therapy, and nerve desensitization. However, these treatments have limitations in fully
Yue Gu+7 more
wiley +1 more source
Background and Objective: Atopic dermatitis is an inherited, chronic and relapsing skin disease. Although it is generally believed that breast-feeding has a protective effect on developing asthma and atopic dermatitis, nowadays, some researchers question
Masoud Dehdashtian+5 more
doaj
Provocation with cow's milk and cereals in atopic dermatitis
H. Hammar
openalex +2 more sources
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki+24 more
wiley +1 more source